Clinical Trials Logo

Clinical Trial Summary

Acute liver failure is a rare but dramatic disease, often affecting young people, marked by the sudden loss of liver function in a person without preexisting liver disease.

ALF-5755 has been shown to promote cell survival after apoptotic or oxidative stress, and liver cell regeneration in primary cultures and in vivo. ALF-5755 may become, in this dramatic disease with high unmet medical need, a future therapy for the treatment of patients suffering from severe acute hepatitis (SAH) and acute liver failure (ALF) not due to acetaminophen overdose, where liver transplantation is the sole treatment in the absence of spontaneous recovery.

The primary objective of the study is to evaluate the efficacy of ALF-5755 versus placebo.

A minimum of 60 patients will be recruited into the study in the following two treatment groups:

- Group A: approximately 30 patients will receive ALF-5755

- Group B: approximately 30 patients will receive placebo (physiological saline solution: 0.9% NaCl)

Patients will receive 10 mg (25 ml) of ALF5755 or placebo every 12 hours over 3 days in slow intravenous infusions over 10 minutes using automatic syringes.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01318525
Study type Interventional
Source Alfact Innovation
Contact Paul Amouyal
Phone +33 1 45 59 35 66
Email amouyal.paul@wanadoo.fr
Status Recruiting
Phase Phase 2
Start date October 2010
Completion date September 2012

See also
  Status Clinical Trial Phase
Recruiting NCT00225901 - Phase I/II Study of Recombinant Human Hepatocyte Growth Factor in Fulminant Hepatic Failure Phase 1/Phase 2
Not yet recruiting NCT05778461 - Efficacy of L-ornithine L-aspartate and Therapeutic Plasma Exchange Versus Plasma Exchange Alone in Lowering Ammonia and Improving Outcomes in Pediatric Acute Liver Failure. N/A
Completed NCT03312036 - HEpatic Regeneration With COupled Plasma Filtration and Adsorption for Liver Extracorporeal Detoxification N/A
Not yet recruiting NCT03084198 - Safety and Efficacy of hiHep Bioartificial Liver Support System to Treat Acute Liver Failure N/A
Recruiting NCT01341951 - Granulocyte Colony Stimulating Factor (G-CSF) in Acute Liver Failure and Alcoholic Hepatitis N/A
Not yet recruiting NCT05473403 - Validation of a Prognostic Score for Steroid Therapy Response in Acute Severe Autoimmune Hepatitis N/A
Completed NCT04959110 - Citrate Pharmacokinetics in Critically Ill Liver Failure Patients Receiving CRRT N/A
Enrolling by invitation NCT01471262 - Right Hepatectomy in Patients Beyond 70 Years Old N/A
Recruiting NCT06263114 - Correlation of Blood Gene Expression (TruGraf Liver) With Liver Biopsy in Pediatric Liver Transplant Recipients
Completed NCT04512014 - Perioperative Lactate Kinetics in Patient Undergoing Major Liver Surgery
Completed NCT02687763 - Safety and Efficacy of ProQuad® in Children 6-24 Month Being Evaluated for Solid Organ Transplant Early Phase 1
Completed NCT02310542 - Comparison of Two Liver Dialysis Systems : MARS Versus SPAD in Severe Liver Failure N/A
Completed NCT01394497 - Use of N-Acetylcysteine During Liver Procurement Phase 2
Completed NCT01878305 - Neuromonitoring of Hepatic Encephalopathy N/A
Not yet recruiting NCT05817994 - Endoscopic Ultrasound Guided Liver Biopsy and Portal Pressure Registry
Withdrawn NCT01137591 - Acetaminophen in Combination With N-Acetylcysteine (NAC) Versus Placebo in Treating Fever N/A